Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 57

1.

Fibroblast growth factor 23 expression in human calcified vascular tissues.

Donate-Correa J, Martín-Núñez E, Hernández-Carballo C, Ferri C, Tagua VG, Delgado-Molinos A, López-Castillo Á, Rodríguez-Ramos S, Cerro-López P, López-Tarruella VC, Felipe-García R, Arévalo-Gomez MA, Pérez-Delgado N, Mora-Fernández C, Navarro-González JF.

Aging (Albany NY). 2019 Sep 22;11(18):7899-7913. doi: 10.18632/aging.102297. Epub 2019 Sep 22.

2.

Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation and Study of Diabetic Nephropathy with Atrasentan: what was learned about the treatment of diabetic kidney disease with canagliflozin and atrasentan?

Fernandez-Fernandez B, Fernandez-Prado R, Górriz JL, Martinez-Castelao A, Navarro-González JF, Porrini E, Soler MJ, Ortiz A.

Clin Kidney J. 2019 May 31;12(3):313-321. doi: 10.1093/ckj/sfz070. eCollection 2019 Jun.

3.

A Novel Heterozygous Deletion Variant in KLOTHO Gene Leading to Haploinsufficiency and Impairment of Fibroblast Growth Factor 23 Signaling Pathway.

Martín-Núñez E, Donate-Correa J, Kannengiesser C, De Brauwere DP, Leroy C, Oudin C, Friedlander G, Prieto-Morín C, Tagua VG, Ureña-Torres PA, Navarro-González JF.

J Clin Med. 2019 Apr 12;8(4). pii: E500. doi: 10.3390/jcm8040500.

4.

FGF23 and Klotho Levels are Independently Associated with Diabetic Foot Syndrome in Type 2 Diabetes Mellitus.

Donate-Correa J, Martín-Núñez E, Ferri C, Hernández-Carballo C, Tagua VG, Delgado-Molinos A, López-Castillo Á, Rodríguez-Ramos S, Cerro-López P, López-Tarruella VC, Arévalo-González MA, Pérez-Delgado N, Mora-Fernández C, Navarro-González JF.

J Clin Med. 2019 Apr 3;8(4). pii: E448. doi: 10.3390/jcm8040448.

5.

Pentoxifylline for Renal Protection in Diabetic Kidney Disease. A Model of Old Drugs for New Horizons.

Donate-Correa J, Tagua VG, Ferri C, Martín-Núñez E, Hernández-Carballo C, Ureña-Torres P, Ruiz-Ortega M, Ortiz A, Mora-Fernández C, Navarro-González JF.

J Clin Med. 2019 Feb 27;8(3). pii: E287. doi: 10.3390/jcm8030287. Review.

6.

Will the new molecules be effective in renal and cardiovascular protection in diabetes mellitus and diabetic kidney disease?

Martinez Martinez-Castelao A, Soler MJ, Navarro-González JF, Górriz JL.

Nefrologia. 2019 Jan - Feb;39(1):3-10. doi: 10.1016/j.nefro.2018.05.011. Epub 2018 Oct 2. English, Spanish. No abstract available.

7.

Inflammation in Diabetic Kidney Disease.

Pérez-Morales RE, Del Pino MD, Valdivielso JM, Ortiz A, Mora-Fernández C, Navarro-González JF.

Nephron. 2019;143(1):12-16. doi: 10.1159/000493278. Epub 2018 Oct 1. Review.

8.

Association of the rs495392 Klotho polymorphism with atheromatosis progression in patients with chronic kidney disease.

Valdivielso JM, Bozic M, Galimudi RK, Bermudez-López M, Navarro-González JF, Fernández E, Betriu À.

Nephrol Dial Transplant. 2019 Dec 1;34(12):2079-2088. doi: 10.1093/ndt/gfy207.

PMID:
30010839
9.

Effects of Pentoxifylline on Soluble Klotho Concentrations and Renal Tubular Cell Expression in Diabetic Kidney Disease.

Navarro-González JF, Sánchez-Niño MD, Donate-Correa J, Martín-Núñez E, Ferri C, Pérez-Delgado N, Górriz JL, Martínez-Castelao A, Ortiz A, Mora-Fernández C.

Diabetes Care. 2018 Aug;41(8):1817-1820. doi: 10.2337/dc18-0078. Epub 2018 Jun 4.

PMID:
29866645
10.

Phenotypic Modulation of Cultured Primary Human Aortic Vascular Smooth Muscle Cells by Uremic Serum.

Cazaña-Pérez V, Cidad P, Donate-Correa J, Martín-Núñez E, López-López JR, Pérez-García MT, Giraldez T, Navarro-González JF, Alvarez de la Rosa D.

Front Physiol. 2018 Feb 12;9:89. doi: 10.3389/fphys.2018.00089. eCollection 2018.

11.

Soluble levels and endogenous vascular gene expression of KLOTHO are related to inflammation in human atherosclerotic disease.

Martín-Núñez E, Donate-Correa J, López-Castillo Á, Delgado-Molinos A, Ferri C, Rodríguez-Ramos S, Cerro P, Pérez-Delgado N, Castro V, Hernández-Carballo C, Mora-Fernández C, Navarro-González JF.

Clin Sci (Lond). 2017 Oct 25;131(21):2601-2609. doi: 10.1042/CS20171242. Print 2017 Nov 1.

PMID:
28963437
12.

ERBP guideline on management of patients with diabetes and chronic kidney disease stage 3B or higher. Metformin for all?

Martínez-Castelao A, Górriz JL, Ortiz A, Navarro-González JF.

Nefrologia. 2017 Nov - Dec;37(6):567-571. doi: 10.1016/j.nefro.2017.06.001. Epub 2017 Jun 29. English, Spanish. No abstract available.

13.

Anti-inflammatory profile of paricalcitol in kidney transplant recipients.

Donate-Correa J, Henríquez-Palop F, Martín-Núñez E, Hernández-Carballo C, Ferri C, Pérez-Delgado N, Muros-de-Fuentes M, Mora-Fernández C, Navarro-González JF.

Nefrologia. 2017 Nov - Dec;37(6):622-629. doi: 10.1016/j.nefro.2017.03.028. Epub 2017 Jun 15. English, Spanish.

14.

Effect of Paricalcitol on FGF-23 and Klotho in Kidney Transplant Recipients.

Donate-Correa J, Henríquez-Palop F, Martín-Núñez E, Pérez-Delgado N, Muros-de-Fuentes M, Mora-Fernández C, Navarro-González JF.

Transplantation. 2016 Nov;100(11):2432-2438.

PMID:
27467536
15.

What is the optimal level of vitamin D in non-dialysis chronic kidney disease population?

Molina P, Górriz JL, Molina MD, Beltrán S, Vizcaíno B, Escudero V, Kanter J, Ávila AI, Bover J, Fernández E, Nieto J, Cigarrán S, Gruss E, Fernández-Juárez G, Martínez-Castelao A, Navarro-González JF, Romero R, Pallardó LM.

World J Nephrol. 2016 Sep 6;5(5):471-81. doi: 10.5527/wjn.v5.i5.471.

16.

Implications of Fibroblast growth factor/Klotho system in glucose metabolism and diabetes.

Donate-Correa J, Martín-Núñez E, Delgado NP, de Fuentes MM, Arduan AO, Mora-Fernández C, Navarro González JF.

Cytokine Growth Factor Rev. 2016 Apr;28:71-7. doi: 10.1016/j.cytogfr.2015.12.003. Epub 2015 Dec 10. Review.

PMID:
26706229
17.

Predictors of Subclinical Atheromatosis Progression over 2 Years in Patients with Different Stages of CKD.

Gracia M, Betriu À, Martínez-Alonso M, Arroyo D, Abajo M, Fernández E, Valdivielso JM; NEFRONA Investigators.

Clin J Am Soc Nephrol. 2016 Feb 5;11(2):287-96. doi: 10.2215/CJN.01240215. Epub 2015 Dec 14.

18.

Klotho in cardiovascular disease: Current and future perspectives.

Donate-Correa J, Martín-Núñez E, Mora-Fernández C, Muros-de-Fuentes M, Pérez-Delgado N, Navarro-González JF.

World J Biol Chem. 2015 Nov 26;6(4):351-7. doi: 10.4331/wjbc.v6.i4.351. Review.

19.

Influence of Klotho gene polymorphisms on vascular gene expression and its relationship to cardiovascular disease.

Donate-Correa J, Martín-Núñez E, Martínez-Sanz R, Muros-de-Fuentes M, Mora-Fernández C, Pérez-Delgado N, Navarro-González JF.

J Cell Mol Med. 2016 Jan;20(1):128-33. doi: 10.1111/jcmm.12710. Epub 2015 Nov 5.

20.

Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data?

Górriz JL, Nieto J, Navarro-González JF, Molina P, Martínez-Castelao A, Pallardó LM.

J Clin Med. 2015 Oct 23;4(10):1866-89. doi: 10.3390/jcm4101866. Review.

Supplemental Content

Loading ...
Support Center